| Bid | 29.1 |
| Market Cap | 4.63B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.1 |
| PE Ratio (ttm) | -297.35 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 31.29 |
| Volume | 4,916,540 |
| Avg. Volume (20D) | 2,966,645 |
| Open | 29.70 |
| Previous Close | 27.67 |
| Day's Range | 28.41 - 30.68 |
| 52-Week Range | 12.84 - 36.84 |
| Beta | undefined |
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra...
Analyst Forecast
According to 6 analyst ratings, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $41.5, which is an increase of 39.57% from the latest price.
Next Earnings Release
Analysts project revenue of $98.13M, reflecting a 123.17% YoY growth and earnings per share of 0.08, making a -188.89% decrease YoY.
2 months ago · seekingalpha.com
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 UpdatesTG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in...
2 months ago · seekingalpha.com
TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares FellTG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal...
